dxpx general logo white text

DxPx Europe '25 Conference for Accelerators/TTOs

A partnering conference for teams looking for visibility and funding for their portfolio companies

Reception: Sunday, January 26th, 2025
Partnering Day & 42PLUS1: January 27th, 2025

Why Accelerators/TTOs Should Attend DxPx Europe '25:

  • Schedule 1×1 meetings for you and your portfolio companies in our private DxPx meeting spaces.
  • Register as an Accelerator/Technology Transfer Office for DxPx Europe for just €1,350 and get 20% off our standard pricing for registration and booth space for up to five (5) of your portfolio companies. 
    • Your portfolio companies can:
      • Exhibit – includes two free registrations when they secure their fully built & custom-branded booth space.
      • Compete in our 42PLUS1 pitch competition for your chance to secure up to $2 million in funding. Learn more at 42PLUS1.com.
  • Network with all DxPx attendees at our Opening Reception on Sunday, January 26th and the DxPx After Party on Monday, January 27th.
  • Learn more about the latest industry trends and market insights from our DxPx panelists and speakers to help you identify future opportunities for your portfolio companies.
  • Grow your portfolio and find your next big opportunity by leveraging all that DxPx Europe ’25 has to offer.

Each Accelerator/TTO registration comes with five 20% off coupon codes that you can share with companies in your network to maximize their visibility at DxPx.

Join the DxPx Ambassador Network to Gain Registration Discounts for Your Portfolio Companies

Learn more and register here.

Date & Location:

Reception: Sunday, January 26th, 2025
Partnering Day & 42PLUS1: January 27th, 2025
Leonardo Royal Hotel Munich Moosacher Straße 90 | 80809 München | Germany

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience